Retrospective diagnosis of lymphatic tuberculosis in frozen samples using two genetic amplification methods, Xpert® MTB/RIF ULTRA and Abbott RealTime MTB Assay

ABSTRACT

Objectives. The main objective of the present study is to assess the sensitivity and specificity of a retrospective diagnostic of lymphatic tuberculosis (LTB), testing frozen samples using gene amplification PCR methods. The secondary objective was to compare the results of two different commercial tuberculosis gene amplification methods for this purpose.

Material and methods. We retrospectively studied 38 frozen samples, previously processed for mycobacterial culture between January 2014 and August 2019. The results of the previous cultures were: 21 samples positive for Mycobacterium tuberculosis complex (MTB) (5 being smear positive), 7 samples culture positive for Mycobacterium avium-intracellulare complex and 10 samples which were mycobacterial culture negative and discarded for LTB diagnosis, used as controls. The samples were processed using two gene amplification methods: Xpert® MTB/RIF Ultra (Cepheid) and Abbott RealTime MTB Assay (Abbott).

Results. Compared to initial culture results the sensitivity and specificity of Xpert® MTB/RIF Ultra were 57.1% and 100% and 52.3% and 92.5%, respectively for the Abbott RealTime MTB assay. The differences were not statistically significant. In addition, there were no differences according to the period of freezing.

Conclusions. Gene amplification of frozen samples confirmed the diagnosis of lymphatic TB in almost 60% of cases, allowing retrospective diagnosis in initially non suspected cases. Both gene amplification techniques tested were equally useful.

Keywords: Frozen lymph nodes samples, retrospective TB diagnosis, Xpert® ULTRA, Abbott RealTime MTB, lymph nodes, extrapulmonary tuberculosis.

Correspondence: Julián Gonzalez-Martin.
Servei de Microbiologia, Hospital Clinic de Barcelona.
C. Villarroel 170, 08036-Barcelona
E-mail: gonzalez@clinic.cat

Diagnóstico retrospectivo de tuberculosis linfática en muestras congeladas utilizando dos métodos de amplificación genética, Xpert MTB/RIF ULTRA y Abbott RealTime MTB Assay

RESUMEN

Objetivos. El principal objetivo del presente estudio es establecer la sensibilidad y especificidad del diagnóstico retrospectivo de tuberculosis linfática (LTB), analizando muestras congeladas y utilizando métodos de amplificación genética basados en PCR. El objetivo secundario es comparar los resultados de dos métodos comercializados de amplificación genética de tuberculosis.

Material y métodos. Se estudiaron retrospectivamente 38 muestras congeladas, que previamente habían sido procesadas para realizar cultivo de micobacterias, entre enero de 2014 y agosto de 2019. Los resultados en ese momento fueron: 21 muestras positivas para Mycobacterium tuberculosis complex (MTB) (de las que 5 tenían la tinción positiva), 7 muestras con cultivo positivo para Mycobacterium avium-intracellulare complex y 10 muestras con cultivo de micobacterias negativo, en las que se había descartado el diagnóstico de LTB, que se usaron como controles. Las muestras se procesaron utilizando dos métodos de amplificación genética: Xpert® MTB/RIF Ultra (Cepheid) y Abbott RealTime MTB Assay (Abbott).

Resultados. Comparando con los resultados de los cultivos iniciales, la sensibilidad y especificidad de Xpert® MTB/RIF Ultra fueron de 57,1% y 100%, y de 52,3% y 92,5%, para Abbott RealTime MTB assay. Las diferencias no fueron estadísticamente significativas. Tampoco se observaron diferencias en relación al periodo transcurrido desde la congelación.

Conclusiones. La amplificación genética de muestras congeladas confirma el diagnóstico de tuberculosis linfática en casi el 60% de los casos, permitiendo el diagnóstico retrospectivo...
The aim of the present study was to study the sensitivity and specificity of a retrospective diagnosis of lymph node TB analysing frozen samples using two NAAT in comparison to the initial mycobacterial culture.

METHODS

Sample collection. The mycobacterial laboratory of the hospital stores aliquots of remaining decontaminated samples processed for mycobacterial culture. Samples are maintained at -80°C and thawed if required for PCR or repeating the culture. In the present study, a total of 38 aliquots of frozen decontaminated lymph node samples, processed for mycobacterial culture between January 2014 and August 2019 were selected and thawed. Twenty-one samples were obtained from tuberculous patients culture-positive for MBT, and 7 samples were obtained from patients suspected of mycobacterial disease who were culture positive for Mycobacterium avium-intracellulare complex (MAC). Ten mycobacterial culture-negative samples obtained from patients with a final diagnosis other than mycobacterial infection were included as controls.

The Xpert® MTB/RIF ULTRA and Abbott RealTime MTB assays were performed in the 38 samples included in the study. Before the amplification tests, a tissue digestion step was performed: 2 mL of the sample were centrifuged for 10 min, and the sediment recovered was then resuspended into 800 µL of digestion buffer with 40 µL of proteinase K (Qiagen, Hilden, Germany), followed by a heating at 56 °C overnight. The digestion volume was adjusted to 1.1 ml and distributed as follows: 0.6 ml of the digested sample were tested for Xpert® MTB/RIF ULTRA using the GeneXpert instrument (Cepheid Sunnyvale, USA), and 0.5 ml were tested with the Abbott RealTime MTB. The results of both methods were interpreted according to the manufacturer’s instructions.

RESULTS

Table 1 shows the results obtained with the two methods. Twelve and 11 of 21 MTB-positive cultures were also positive by Xpert® MTB/RIF ULTRA and Abbott RealTime MTB, respectively. Two additional positives of Abbott RealTime MTB were considered false positives, one of the controls and one of the MAC positive cultures. Compared to culture, the overall sensitivity and specificity for Xpert® MTB/RIF ULTRA were 57.1% and 100%, respectively, being 52.3% and 92.5% for the Abbott RealTime MTB. The differences were not statically significant. Of 21 samples positive for MTB, five were also positive by staining. These samples were among the positive NAAT results. There were no differences in the results according to the date of freezing.

DISCUSSION

In the present study, we analysed frozen aliquots remaining from decontaminated samples processed for mycobacterial culture to retrospectively diagnose lymphatic TB. The samples were analysed using two commercial NAAT [4,8], obtaining a sensitivity of 57.1% for Xpert® MTB/RIF Ultra and 52.3% for Abbott RealTime MTB. These results support the utility of a retrospective diagnosis for cases with clinical and/or histological suspicion of TB, days or weeks after processing a sample initially suspected of pathologies other than TB.

Both of the NAAT used in this study have been tested for diagnosing pulmonary TB. The new and old Xpert® versions, have been broadly tested [5,6], achieving a sensitivity of 89%...
and a specificity of 99%. In addition, Abbott RealTime MTB has been used in several studies [8-10], showing a sensitivity of around 80%. Another study comparing both methods found equivalent results [11].

Several studies in the literature have described the results of NAAT in diagnosing lymphatic TB in fresh samples [4,7]. A Cochrane review [4] using Xpert® MTB/RIF Ultra reported a sensitivity of 70 to 81.6% with a specificity of 96.4-100%. Although the sensitivity results of the present study were lower than those achieved in fresh samples, they were comparable to other studies performed using paraffin-embedded biopsies. Moure et al [12] found a sensitivity of 60% and a specificity of 85.7%. Although the present study included samples frozen between 1 and 5 years previously, the results were independent of the freezing time. Among the few studies including fresh samples, some did not observe differences with respect to fresh samples [10,13]. It should however be noted that these studies included smear positive samples, with a high bacterial load. It has been suggested, that bacterial viability may be reduced in frozen samples due to autolysis of mycobacterial cells [14], and DNA degradation cannot be ruled out either. This reduction in viability would be evidenced only in paucibacillary samples, such as those from extrapulmonary sites, in which the bacterial load can be critical to decide a positive or negative result. Therefore, we hypothesized that freezing without measures to prevent bacterial autolysis could play a role in the decreased sensitivity found in the present study. On the other hand, processing frozen aliquots of remaining decontaminated culture samples not only from lymph nodes, can confirm a diagnosis of TB, weeks or months after obtaining the sample.

In conclusion, gene amplification performed in frozen samples allows confirmation of a diagnosis of TB weeks or months after obtaining the sample. For this purpose, both Xpert® MTB/RIF Ultra and Abbott MTB assays showed equivalent results.

**ACKNOWLEDGEMENTS**

The authors belong to the Study Group of Mycobacterial Infections (GEIM) of the Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC), the Spanish Network for the Research in Infectious Diseases (REIPI) and the research team award for quality control by Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, 2017SGR809). IS-Global is a member of the CERCA Programme, Generalitat de Catalunya. In addition, we are deeply grateful to Donna Pringle for her help with language revision.

**FUNDING**

This work was supported by the Ministerio de Economía y Competitividad, Instituto de Salud Carlos III, Subdirección General de Redes y Centro de Investigación Cooperativa, co-financed by the European Regional Development Fund (ERDF) ‘A way to achieve Europe’, the Spanish Ministry of Health (grant no. PI16/01047), Planes Nacionales de I+D+i 2008-2011/2013-2016 and the Spanish Network for Research in Infectious Diseases (REIPI) (RD16/0016/0010) co-financed by ERDF and operative program Intelligent Growth 2014-2020. This study was also supported by grant 2017SGR809 from the Departament d’Universitats, Recerca i Societat de la Informació de la Generalitat de Catalunya, and by a grant from Fundació La Marató de TV3 (grant no. 202816-10).

**CONFLICTS OF INTEREST**

The authors declare that they have no conflicts of interest.

**REFERENCES**

1. World health organization. Global Tuberculosis Report. 2020 Available from: https://www.who.int/publications/i/item/9789240013131
2. Lazarus AA and Thilagar B. Tuberculous lymphadenitis. Dis
Retrospective diagnosis of lymphatic tuberculosis in frozen samples using two genetic amplification methods, Xpert® MTB/RIF ULTRA and Abbott RealTime MTB Assay

M. Fernandez-Pittol, et al.
Rev Esp Quimioter 2021;34(6): 660-663

3. World health organization. Improving the diagnosis and treatment of smear negative pulmonary and extrapulmonary tuberculosis among adults and adolescents. Recommendations for HIV-prevalent and resource-constrained settings. WHO/HTM/TB/2007.379. Available from: https://apps.who.int/iris/handle/10665/69463

4. Horne DJ, Kohli M, Zifodya JS, Schiller I, Dendukuri N, Tollefson D et al. Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2019;6:CD009593. doi: 10.1002/14651858.CD009593.pub4.

5. Arend SM, van Soolingen D. Performance of Xpert MTB/RIF Ultra: a matter of dead or alive. Lancet Infect Dis. 2018;18:8-10. doi: 10.1016/S1473-3099(17)30695-3.

6. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2014(1):CD009593. doi: 10.1002/14651858.CD009593.pub3.

7. Perez-Risco D, Rodriguez-Temporal D, Valledor-Sanchez I, Alcaide F. Evaluation of the Xpert MTB/RIF Ultra Assay for Direct Detection of Mycobacterium tuberculosis Complex in Smear-Negative Extrapulmonary Samples. J Clin Microbiol. 2018; 56:e00659-18. doi: 10.1128/JCM.00659-18.

8. Vinuesa V, Navarro D, Poujos S, Zaragoza S, Borrás R. Performance characteristics of the new Abbott Real Time MTB assay for detection of Mycobacterium tuberculosis complex in respiratory specimens. Diagn Microbiol Infect Dis. 2016; 84:212-4. doi: 10.1016/j.diagmicrobio.2015.11.001.

9. Ruiz P, Causse M, Vaquero M, Gutierrez JB, Casal M. Evaluation of a new automated Abbott RealTime MTB Rif/INH assay for qualitative detection of rifampicin/isoniazid resistance in pulmonary and extra-pulmonary clinical samples of Mycobacterium tuberculosis. Infect Drug Resist. 2017; 10:463-467. doi: 10.2147/IDR.S147272.

10. Hinić V, Feuz K, Turan S, Berini A, Frei R, Pfeifer K, et al. Clinical evaluation of the Abbott Real Time MTB Assay for direct detection of Mycobacterium tuberculosis-complex from respiratory and non-respiratory samples. Tuberculosis. 2017;104:65–9. doi: 10.1016/j.tube.2017.03.002.

11. Berhanu RH, David A, da Silva P, Shearer K, Sanne I, Stevens W, et al. Performance of Xpert MTB/RIF, Xpert Ultra, and Abbott Real-Time MTB for diagnosis of pulmonary tuberculosis in a high-HIV-burden setting. J Clin Microbiol. 2017; 259:10-15. doi: 10.1016/j.jcm.2016.11.006.

12. Moure Z, Castelví J, Sanchez-Montalva A, Pumarola T and Tortola MT. The role of molecular techniques for the detection of Mycobacterium tuberculosis complex in paraffin-embedded biopsies. Appl Immunohistochem Mol Morphol 2019; 27:77-80. doi: 10.1097/ PAI.0000000000000533.

13. Atwebembeire J, Onikiriza P, Bonnet M, Atwine D, Katawera V, Nansumba M, et al. Xpert® MTB/RIF for detection of Mycobacterium tuberculosis from frozen string and induced sputum sediments. Int J Tuberc Lung Dis. 2016; 20:1113-7. doi: 10.5888/ijtld.15.0691.

14. Pahtak D, Chakravorty S, Hanif M and Tyagi JS. Lysis of tubercle bacilli in fresh and stored sputum specimens: implications for diagnosing tuberculosis in stored and paucibacillary specimens by PCR. BMC Microbiology. 2007; 7:83. doi: 10.1186/1471-2180-7-83.